Investors with a lot of money to spend have taken a bullish stance on Teva Pharmaceutical Indus TEVA.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TEVA, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 8 uncommon options trades for Teva Pharmaceutical Indus.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 37%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $635,855, and 3 are calls, for a total amount of $149,140.
Projected Price Targets
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $16.0 to $21.0 for Teva Pharmaceutical Indus over the last 3 months.
Volume & Open Interest Trends
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Teva Pharmaceutical Indus's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Teva Pharmaceutical Indus's substantial trades, within a strike price spectrum from $16.0 to $21.0 over the preceding 30 days.
Teva Pharmaceutical Indus 30-Day Option Volume & Interest Snapshot
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TEVA | PUT | SWEEP | BULLISH | 02/21/25 | $3.1 | $2.94 | $2.95 | $21.00 | $295.1K | 5.2K | 3.0K |
| TEVA | PUT | SWEEP | BEARISH | 03/21/25 | $0.77 | $0.68 | $0.77 | $18.00 | $180.1K | 26.3K | 2.4K |
| TEVA | CALL | SWEEP | BEARISH | 06/20/25 | $3.2 | $3.15 | $3.2 | $16.00 | $79.6K | 434 | 279 |
| TEVA | PUT | SWEEP | NEUTRAL | 02/21/25 | $3.05 | $2.95 | $3.0 | $21.00 | $74.7K | 5.2K | 250 |
| TEVA | PUT | SWEEP | BEARISH | 03/21/25 | $0.52 | $0.48 | $0.52 | $17.00 | $52.0K | 2.7K | 3.5K |
About Teva Pharmaceutical Indus
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Following our analysis of the options activities associated with Teva Pharmaceutical Indus, we pivot to a closer look at the company's own performance.
Teva Pharmaceutical Indus's Current Market Status
- With a volume of 23,352,592, the price of TEVA is up 0.22% at $18.58.
- RSI indicators hint that the underlying stock may be oversold.
- Next earnings are expected to be released in 97 days.
Expert Opinions on Teva Pharmaceutical Indus
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $28.666666666666668.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from UBS persists with their Buy rating on Teva Pharmaceutical Indus, maintaining a target price of $30. * An analyst from Barclays persists with their Overweight rating on Teva Pharmaceutical Indus, maintaining a target price of $26. * Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Teva Pharmaceutical Indus with a target price of $30.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Teva Pharmaceutical Indus with Benzinga Pro for real-time alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
